Immune response to lipoproteins in atherosclerosis

Cholesterol

Volumn 2012, Issue , 2012, Pages

  Samson, Sonia ^a   Mundkur, Lakshmi ^a   Kakkar, Vijay V ^a,b  

^a Narayana Health City   (India)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B VACCINE; APOLIPOPROTEIN B100; APOLIPOPROTEIN B100 VACCINE; ATHEROSCLEROSIS VACCINE; CHOLESTEROL; CYTOKINE; HEAT SHOCK PROTEIN 60 VACCINE; HUMAN RECOMBINANT IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOPROTEIN; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN IMMUNOGLOBULIN M ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN VACCINE; OXIDIZED PHOSPHOLIPID VACCINE; PEPTIDE VACCINE; PHOSPHOLIPID ANTIBODY; PHOSPHORYLCHOLINE MONOCLONAL ANTIBODY; PHOSPHORYLCHOLINE VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT ANTIBODY; RECOMBINANT APOLIPOPROTEIN B100 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROPROTECTIVE IMMUNE RESPONSE; ATHEROSCLEROSIS; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG ACTIVITY; ENZYMATIC DEGRADATION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INNATE IMMUNITY; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROATHEROGENIC IMMUNE RESPONSE; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84866148828     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2012/571846     Document Type: Review

References (118)

1. Greenland P., Knoll M. D., Stamler J., Neaton J. D., Dyer A. R., Garside D. B., Wilson P. W., Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Journal of the American Medical Association 2003 290 7 891 897 2-s2.0-0042195833 10.1001/jama.290.7.891 (Pubitemid 37430460)
2. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696 (Pubitemid 32433843)
3. Baigent C., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 2005 366 9493 1267 1278 2-s2.0-26244432388 10.1016/S0140-6736(05)67394-1 (Pubitemid 41416582)
4. Paoletti R., Gotto A. M., Hajjar D. P., Inflammation in atherosclerosis and implications for therapy. Circulation 2004 109 23, supplement III20 III26 2-s2.0-2942701875 (Pubitemid 38786439)
5. Hansson G. K., Libby P., The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 2006 6 7 508 519 2-s2.0-33745571976 10.1038/nri1882 (Pubitemid 43980523)
6. Cuneo A. A., Autieri M. V., Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury. Current Vascular Pharmacology 2009 7 3 267 276 2-s2.0-69149085564 10.2174/ 157016109788340721
7. Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 2005 352 16 1685 1695 2-s2.0-17644412023 10.1056/NEJMra043430 (Pubitemid 40530235)
8. Steinberg D., Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nature Medicine 2002 8 11 1211 1217 2-s2.0-0036853543 10.1038/nm1102-1211 (Pubitemid 35373551)
9. Schwenke D. C., Carew T. E., Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 1989 9 6 908 918 2-s2.0-0024306039 (Pubitemid 20002223)
10. Olin-Lewis K., Krauss R. M., La Belle M., Blanche P. J., Hugh R Barrett P., Wight T. N., Chait A., ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. Journal of Lipid Research 2002 43 11 1969 1977 2-s2.0-0036846061 10.1194/jlr.M200322-JLR200 (Pubitemid 35315815)
11. Hevonoja T., Pentikäinen M. O., Hyvönen M. T., Kovanen P. T., Ala-Korpela M., Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochimica et Biophysica Acta 2000 1488 3 189 210 2-s2.0-0034669402 10.1016/S1388-1981(00)00123-2
12. Riley E., Dasari V., Frishman W. H., Sperber K., Vaccines in development to prevent and treat atherosclerotic disease. Cardiology in Review 2008 16 6 288 300 2-s2.0-58149314083 10.1097/CRD.0b013e3181885933
13. Gu L., Okada Y., Clinton S. K., Gerard C., Sukhova G. K., Libby P., Rollins B. J., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell 1998 2 2 275 281 2-s2.0-0032134003 (Pubitemid 128373654)
14. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998 394 6696 894 897 2-s2.0-0032572719 10.1038/29788 (Pubitemid 28410911)
15. Hansson G. K., Hermansson A., The immune system in atherosclerosis. Nature Immunology 2011 12 3 204 212 2-s2.0-79951669207 10.1038/ni.2001
16. Xu Q., Role of heat shock proteins in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 10 1547 1559 2-s2.0-0036790571 10.1161/01.ATV.0000029720.59649.50
17. Stemme S., Hansson G. K., Immune mechanisms in atherosclerosis. Coronary Artery Disease 1994 5 3 216 222 2-s2.0-0028297456 (Pubitemid 24116854)
18. De Boer O. J., Van der Wal A. C., Houtkamp M. A., Ossewaarde J. M., Teeling P., Becker A. E., Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovascular Research 2000 48 3 402 408 2-s2.0-0033708635 10.1016/S0008-6363(00)00195-4
19. Robertson A. K. L., Hansson G. K., T cells in atherogenesis: for better or for worse? Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 11 2421 2432 2-s2.0-33750203252 10.1161/01.ATV.0000245830.29764.84 (Pubitemid 44607461)
20. Frostegård J., Ulfgren A. K., Nyberg P., Hedin U., Swedenborg J., Andersson U., Hansson G. K., Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999 145 1 33 43 2-s2.0-0033048632 10.1016/S0021-9150(99)00011-8 (Pubitemid 29292698)
21. Methe H., Brunner S., Wiegand D., Nabauer M., Koglin J., Edelman E. R., Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. Journal of the American College of Cardiology 2005 45 12 1939 1945 2-s2.0-20444458026 10.1016/j.jacc.2005.03.040 (Pubitemid 40814112)
22. Agrawal D. K., Shao Z., Pathogenesis of allergic airway inflammation. Current Allergy and Asthma Reports 2010 10 1 39 48 2-s2.0-76649112727 10.1007/s11882-009-0081-7
23. Huber S. A., Sakkinen P., David C., Newell M. K., Tracy R. P., T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001 103 21 2610 2616 2-s2.0-0035967480 (Pubitemid 32521973)
24. -/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 3 456 461 2-s2.0-0036124714 10.1161/hq0302.104905 (Pubitemid 34218754)
25. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005 6 11 1123 1132 2-s2.0-27544490377 10.1038/ni1254 (Pubitemid 41541790)
26. Park H., Li Z., Yang X. O., Chang S. H., Nurieva R., Wang Y. H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology 2005 6 11 1133 1141 2-s2.0-27544465354 10.1038/ni1261 (Pubitemid 41541791)
27. Cheng X., Yu X., Ding Y.-j., Fu Q.-q., Xie J.-j., Tang T.-t., Yao R., Chen Y., Liao Y.-h., The Th17/Treg imbalance in patients with acute coronary syndrome. Clinical Immunology 2008 127 1 89 97 2-s2.0-40849130955 10.1016/j.clim.2008.01.009
28. + regulatory T cells: selfishness under scrutiny. Immunity 2007 27 3 417 419 2-s2.0-34548680982 10.1016/j.immuni.2007.08.008 (Pubitemid 47418676)
29. + T regulatory cell-mediated suppression. Immunity 2009 30 5 636 645 2-s2.0-65549136983 10.1016/j.immuni. 2009.04.010
30. Andersson J., Libby P., Hansson G. K., Adaptive immunity and atherosclerosis. Clinical Immunology 2010 134 1 33 46 2-s2.0-71649108018 10.1016/j.clim.2009.07.002
31. Binder C. J., Chang M. K., Shaw P. X., Miller Y. I., Hartvigsen K., Dewan A., Witztum J. L., Innate and acquired immunity in atherogenesis. Nature Medicine 2002 8 11 1218 1226 2-s2.0-0036852824 10.1038/nm1102-1218 (Pubitemid 35373552)
32. Binder C. J., Shaw P. X., Chang M.-K., Boullier A., Hartvigsen K., Hörkkö S., Miller Y. I., Woelkers D. A., Corr M., Witztum J. L., The role of natural antibodies in atherogenesis. Journal of Lipid Research 2005 46 7 1353 1363 2-s2.0-24744462348 10.1194/jlr.R500005-JLR200 (Pubitemid 43109798)
33. Getz G. S., Bridging the innate and adaptive immune systems. Journal of Lipid Research 2005 46 4 619 622 2-s2.0-21744440568 10.1194/jlr.E500002-JLR200 (Pubitemid 43073270)
34. Getz G. S., Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. Journal of Lipid Research 2005 46 1 1 10 2-s2.0-28744452151
35. Hansson G. K., Immune and inflammatory mechanisms in the pathogenesis of atherosclerosis. Journal of Atherosclerosis and Thrombosis 1994 1 supplement S6 S9 2-s2.0-0028677413
36. Hansson G. K., Immune mechanisms in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 12 1876 1890 2-s2.0-0035571606 (Pubitemid 34219736)
37. Hansson G. K., Regulation of immune mechanisms in atherosclerosis. Annals of the New York Academy of Sciences 2001 947 157 166 2-s2.0-0035683504 (Pubitemid 34059911)
38. Hansson G. K., Atherosclerosis-An immune disease. The Anitschkov Lecture 2007. Atherosclerosis 2009 202 1 2 10 2-s2.0-57849117801 10.1016/j. atherosclerosis.2008.08.039
39. Hansson G. K., Inflammatory mechanisms in atherosclerosis. Journal of Thrombosis and Haemostasis 2009 7 supplement 1 328 331 2-s2.0-67849088725 10.1111/j.1538-7836.2009.03416.x
40. Libby P., Inflammation in atherosclerosis. Nature 2002 420 6917 868 874 2-s2.0-0037180771 10.1038/nature01323 (Pubitemid 36019640)
41. Libby P., Ridker P. M., Hansson G. K., Inflammation in atherosclerosis. From pathophysiology to practice. Journal of the American College of Cardiology 2009 54 23 2129 2138 2-s2.0-70450189795 10.1016/j.jacc.2009.09.009
42. Hansson G. K., Robertson A.-K. L., Söderberg-Nauclér C., Inflammation and atherosclerosis. Annual Review of Pathology 2006 1 297 329 2-s2.0-33645729560 10.1146/annurev.pathol.1.110304.100100
43. Shaw P. X., Hörkkö S., Chang M. K., Curtiss L. K., Palinski W., Silverman G. J., Witztum J. L., Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. Journal of Clinical Investigation 2000 105 12 1731 1740 2-s2.0-0342939538 (Pubitemid 30421754)
44. Palinski W., Witztum J. L., Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. Journal of Internal Medicine 2000 247 3 371 380 2-s2.0-0034035885 10.1046/j.1365-2796.2000. 00656.x (Pubitemid 30180039)
45. Esterbauer H., Dieber-Rotheneder M., Waeg G., Striegl G., Jurgens G., Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chemical Research in Toxicology 1990 3 2 77 92 2-s2.0-0025282662 10.1021/tx00014a001 (Pubitemid 20220286)
46. Yia-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D., Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Journal of Clinical Investigation 1989 84 4 1086 1095 2-s2.0-0024439446 (Pubitemid 19247577)
47. Gharavi N. M., Alva J. A., Mouillesseaux K. P., Lai C., Yeh M., Yeung W., Johnson J., Szeto W. L., Hong L., Fishbein M., Wei L., Pfeffer L. M., Berliner J. A., Role of the JAK/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. Journal of Biological Chemistry 2007 282 43 31460 31468 2-s2.0-35748946958 10.1074/jbc.M704267200 (Pubitemid 350044874)
48. Svensjö E., Boschcov P., Ketelhuth D. F. J., Jancar S., Gidlund M., Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflammation Research 2003 52 5 215 220 2-s2.0-0038174686 (Pubitemid 36712966)
49. Ketelhuth D. F. J., Hansson G. K., Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thrombosis and Haemostasis 2011 106 5 779 786 2-s2.0-80155214095 10.1160/TH11-05-0321
50. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L., Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New England Journal of Medicine 1989 320 14 915 924 2-s2.0-0024603895 (Pubitemid 19101597)
51. Hansson G. K., Vaccination against atherosclerosis: acience or fiction? Circulation 2002 106 13 1599 1601 2-s2.0-0037167692 10.1161/01.CIR.0000035275. 64667.A3
52. Stemme S., Faber B., Holm J., Wiklund O., Witztum J. L., Hansson G. K., T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1995 92 9 3893 3897 2-s2.0-0029053557
53. Toshima S.-I., Hasegawa A., Kurabayashi M., Itabe H., Takano T., Sugano J., Shimamura K., Kimura J., Michishita I., Suzuki T., Nagai R., Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 10 2243 2247 2-s2.0-0033789815
54. Holvoet P., Vanhaecke J., Janssens S., Van De Werf F., Collen D., Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998 98 15 1487 1494 2-s2.0-0032514728 (Pubitemid 28481664)
55. Boyd H. C., Gown A. M., Wolfbauer G., Chait A., Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. American Journal of Pathology 1989 135 5 815 825 2-s2.0-0024381339 (Pubitemid 20009491)
56. Cushing S. D., Berliner J. A., Valente A. J., Territo M. C., Navab M., Parhami F., Gerrity R., Schwartz C. J., Fogelman A. M., Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America 1990 87 13 5134 5138 2-s2.0-0025281588 10.1073/pnas.87.13.5134 (Pubitemid 20224287)
57. Steinberg D., The LDL modification hypothesis of atherogenesis: an update. Journal of Lipid Research 2009 50 S376 S381 2-s2.0-66349100479 10.1194/jlr.R800087-JLR200
58. Dennis E. A., Witztum J. L., Fifty years of research on lipids. Journal of Lipid Research 2009 50 supplement S1 2-s2.0-66349127678 10.1194/jlr. SUPPEDITORIAL-50/4-JLR
59. Baumgarth N., Tung J. W., Herzenberg L. A., Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Seminars in Immunopathology 2005 26 4 347 362 2-s2.0-16344380083 10.1007/s00281-004-0182-2 (Pubitemid 40468889)
60. Masmoudi H., Mota-Santos T., Huetz F., Coutinho A., Cazenave P. A., All T15 Id-positive antibodies (but not the majority of V(H)T15+ antibodies) are produced by peritoneal CD5+ B lymphocytes. International Immunology 1990 2 6 515 520 2-s2.0-0025286142 (Pubitemid 20218428)
61. Casali P., Burastero S. E., Nakamura M., Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987 236 4797 77 81 2-s2.0-0023127468 (Pubitemid 17056816)
62. Hayakawa K., Asano M., Shinton S. A., Gui M., Wen L. J., Dashoff J., Hardy R. R., Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development. Journal of Experimental Medicine 2003 197 1 87 99 2-s2.0-0037240911 10.1084/jem.20021459 (Pubitemid 36110260)
63. Berland R., Wortis H. H., Origins and functions of B-1 cells with notes on the role of CD5. Annual Review of Immunology 2002 20 253 300 2-s2.0-0036217975 10.1146/annurev.immunol.20.100301.064833 (Pubitemid 34293426)
64. Bos N. A., Cebra J. J., Kroese F. G. M., B-1 cells and the intestinal microflora. Current Topics in Microbiology and Immunology 2000 252 211 220 2-s2.0-0033762906
65. Lalor P. A., Morahan G., The peritoneal Ly-1 (CD5) B cell repertoire is unique among murine B cell repertoires. European Journal of Immunology 1990 20 3 485 492 2-s2.0-0025267165 (Pubitemid 20101285)
66. Herzenberg L. A., Herzenberg L. A., Toward a layered immune system. Cell 1989 59 6 953 954 2-s2.0-0024851881 10.1016/0092-8674(89)90748-4 (Pubitemid 20024606)
67. Palinski W., Hörkkö S., Miller E., Steinbrecher U. P., Powell H. C., Curtiss L. K., Witztum J. L., Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. Journal of Clinical Investigation 1996 98 3 800 814 2-s2.0-0029957467 (Pubitemid 26349186)
68. Palinski W., Tangirala R. K., Miller E., Young S. G., Witztum J. L., Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 10 1569 1576 2-s2.0-0029097852
69. Salonen J. T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., Witztum J. L., Autoantibody against oxidised LDL and progression of carotid atherosclerosis. The Lancet 1992 339 8798 883 887 2-s2.0-0026586813
70. Palinski W., Ord V. A., Plump A. S., Breslow J. L., Steinberg D., Witztum J. L., ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arteriosclerosis and Thrombosis 1994 14 4 605 616 2-s2.0-0028198105
71. Friedman P., Hörkkö S., Steinberg D., Witztum J. L., Dennis E. A., Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. Journal of Biological Chemistry 2002 277 9 7010 7020 2-s2.0-0036510381 10.1074/jbc.M108860200 (Pubitemid 34953088)
72. Hörkkö S., Bird D. A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J. A., Friedman P., Dennis E. A., Curtiss L. K., Palinski W., Witztum J. L., Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. Journal of Clinical Investigation 1999 103 1 117 128 2-s2.0-0037896283 (Pubitemid 29031170)
73. Binder C. J., Hörkkö S., Dewan A., Chang M. K., Kieu E. P., Goodyear C. S., Shaw P. X., Palinski W., Witztum J. L., Silverman G. J., Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nature Medicine 2003 9 6 736 743 2-s2.0-0038375997 10.1038/nm876 (Pubitemid 36749223)
74. Caligiuri G., Khallou-Laschet J., Vandaele M., Gaston A. T., Delignat S., Mandet C., Kohler H. V., Kaveri S. V., Nicoletti A., Phosphorylcholine- targeting immunization reduces atherosclerosis. Journal of the American College of Cardiology 2007 50 6 540 546 2-s2.0-34547189707 10.1016/j.jacc.2006.11.054 (Pubitemid 47126777)
75. -/- mice. Journal of the American College of Cardiology 2007 50 24 2313 2318 2-s2.0-36649010572 10.1016/j.jacc.2007.07.081 (Pubitemid 350199611)
76. Hulthe J., Bokemark L., Fagerberg B., Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1 101 107 2-s2.0-0035151814 (Pubitemid 32063236)
77. Karvonen J., Päivänsalo M., Kesäniemi Y. A., Hörkkö S., Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003 108 17 2107 2112 2-s2.0-0242381313 10.1161/01.CIR.0000092891.55157.A7 (Pubitemid 37337587)
78. Faria-Neto J. R., Chyu K. Y., Li X., Dimayuga P. C., Ferreira C., Yano J., Cercek B., Shah P. K., Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006 189 1 83 90 2-s2.0-33749147435 10.1016/j.atherosclerosis.2005.11.033 (Pubitemid 44468069)
79. Zhang M., Austen W. G., Chiu I., Alicot E. M., Hung R., Ma M., Verna N., Xu M., Hechtman H. B., Moore F. D., Carroll M. C., Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2004 101 11 3886 3891 2-s2.0-12144288609 10.1073/pnas.0400347101 (Pubitemid 38381072)
80. Zhao D., Ogawa H., Wang X., Cameron G. S., Baty D. E., Dlott J. S., Triplett D. A., Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. American Journal of Clinical Pathology 2001 116 5 760 767 2-s2.0-0035736459 10.1309/1RYQ-Q2AJ-CKF7-YCDE (Pubitemid 34453219)
81. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M., Komatsu R., Matsuo T., Itabe H., Takano T., Tsukamoto Y., Yoshiyama M., Takeuchi K., Yoshikawa J., Becker A. E., Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001 103 15 1955 1960 2-s2.0-0035901582 (Pubitemid 32322222)
82. George J., Shoenfeld Y., Afek A., Gilburd B., Keren P., Shaish A., Kopolovic J., Wick G., Harats D., Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 3 505 510 2-s2.0-0032976306 (Pubitemid 29135148)
83. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., Barshack I., Kopolovic J., Shoenfeld Y., Immunolocalization of β 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999 99 17 2227 2230 2-s2.0-0032587108 (Pubitemid 29201126)
84. Bergmark C., Wu R., De Faire U., Lefvert A. K., Swedenborg J., Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 4 441 445 2-s2.0-0028923681
85. Monaco C., Crea F., Niccoli G., Summaria F., Cianflone D., Bordone R., Bellomo G., Maseri A., Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: pathophysiological implications. European Heart Journal 2001 22 17 1572 1577 2-s2.0-0034878191 10.1053/euhj.2000.2554 (Pubitemid 32801302)
86. Yla-Herttuala S., Palinski W., Butler S. W., Picard S., Steinberg D., Witztum J. L., Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arteriosclerosis and Thrombosis 1994 14 1 32 40 2-s2.0-0028098153
87. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., Lefvert A. K., Antibodies against cardiolipin and oxidatively modified LDL in 50-year- old men predict myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 11 3159 3163 2-s2.0-0031459413 (Pubitemid 28016072)
88. Puurunen M., Mänttäri M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., Vaarala O., Aho K., Palosuo T., Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Archives of Internal Medicine 1994 154 22 2605 2609 2-s2.0-0027971549 10.1001/archinte.154.22.2605 (Pubitemid 24362412)
89. Fang J. C., Kinlay S., Behrendt D., Hikita H., Witztum J. L., Selwyn A. P., Ganz P., Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 12 2044 2048 2-s2.0-0036928284 10.1161/01.ATV.0000040854.47020.44 (Pubitemid 36025212)
90. Swets B. P., Brouwer D. A. J., Cohen Tervaert J. W., Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clinical and Experimental Immunology 2001 124 1 163 167 2-s2.0-0035009320 10.1046/j.1365-2249.2001.01488.x (Pubitemid 32476947)
91. Wu R., Shoenfeld Y., Sherer Y., Patnaik M., Matsuura E., Gilburd B., Koike T., Peter J. B., Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparationspossible immunomodulation of atherosclerosis. Autoimmunity 2003 36 2 91 97 2-s2.0-0344089215 10.1080/0891693031000080228 (Pubitemid 36394878)
92. Wu R., Svenungsson E., Gunnarsson I., Haegerstrand-Gillis C., Andersson B., Lundberg I., Elinder L. S., Frostegård J., Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and β 2-glycoprotein I (β 2-GPI) in systemic lupus erythematosus. Clinical and Experimental Immunology 1999 115 3 561 566 2-s2.0-0032997715 10.1046/j.1365-2249.1999.00830.x (Pubitemid 29130376)
93. Fredrikson G. N., Hedblad B., Berglund G., Alm R., Nilsson J. Å., Schiopu A., Shah P. K., Nilsson J., Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007 38 5 1495 1500 2-s2.0-34247553751 10.1161/STROKEAHA.106. 474577 (Pubitemid 46684151)
94. Hulthe J., Wikstrand J., Lidell A., Wendelhag I., Hansson G. K., Wiklund O., Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 8 1203 1211 2-s2.0-0031817689 (Pubitemid 28376176)
95. Steinbrecher U. P., Parthasarathy S., Leake D. S., Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the United States of America 1984 81 12 I 3883 3887 2-s2.0-0000061171 (Pubitemid 14087823)
96. Virella G., Virella I., Leman R. B., Pryor M. B., Lopes-Virella M. F., Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. International Journal of Clinical & Laboratory Research 1993 23 1-4 95 101 2-s2.0-0027352741 10.1007/BF02592290
97. Ameli S., Hultgårdh-Nilsson A., Regnström J., Calara F., Yano J., Cercek B., Shah P. K., Nilsson J., Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 8 1074 1079 2-s2.0-0029793720 (Pubitemid 26266910)
98. Palinski W., Miller E., Witztum J. L., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 1995 92 3 821 825 2-s2.0-0028895573 10.1073/pnas.92.3.821
99. Caligiuri G., Nicoletti A., Poirierand B., Hansson G. K., Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. Journal of Clinical Investigation 2002 109 6 745 753 2-s2.0-0036193513 10.1172/JCI200207272 (Pubitemid 34263151)
100. Zhou X., Caligiuri G., Hamsten A., Lefvert A. K., Hansson G. K., LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1 108 114 2-s2.0-0035170994 (Pubitemid 32061934)
101. Schiopu A., Bengtsson J., Söderberg I., Janciauskiene S., Lindgren S., Ares M. P. S., Shah P. K., Carlsson R., Nilsson J., Fredrikson G. N., Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004 110 14 2047 2052 2-s2.0-20844432027 10.1161/01.CIR.0000143162.56057.B5 (Pubitemid 39331920)
102. Nicolo D., Goldman B. I., Monestier M., Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis and Rheumatism 2003 48 10 2974 2978 2-s2.0-0142103926 10.1002/art.11255 (Pubitemid 37280627)
103. Shoenfeld Y., Wu R., Dearing L. D., Matsuura E., Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004 110 17 2552 2558 2-s2.0-7544229779 10.1161/01.CIR.0000143225.07377.EA (Pubitemid 39453000)
104. Shoji T., Nishizawa Y., Fukumoto M., Shimamura K., Kimura J., Kanda H., Emoto M., Kawagishi T., Morii H., Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000 148 1 171 177 2-s2.0-0033990553 10.1016/S0021-9150(99)00218-X
105. Fukumoto M., Shoji T., Emoto M., Kawagishi T., Okuno Y., Nishizawa Y., Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 3 703 707 2-s2.0-0034061545 (Pubitemid 30151684)
106. Klingenberg R., Lebens M., Hermansson A., Fredrikson G. N., Strodthoff D., Rudling M., Ketelhuth D. F. J., Gerdes N., Holmgren J., Nilsson J., Hansson G. K., Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 5 946 952 2-s2.0-77951433369 10.1161/ATVBAHA.109.202671
107. Maron R., Sukhova G., Faria A. M., Hoffmann E., Mach F., Libby P., Weiner H. L., Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002 106 13 1708 1715 2-s2.0-0037167684 10.1161/01.CIR.0000029750.99462.30
108. Nilsson J., Fredrikson G. N., Björkbacka H., Chyu K. Y., Shah P. K., Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. Journal of Internal Medicine 2009 266 3 221 231 2-s2.0-68949118039 10.1111/j.1365-2796.2009.02150.x
109. Van Puijvelde G. H. M., Hauer A. D., De Vos P., Van Den Heuvel R., Van Herwijnen M. J. C., Van Der Zee R., Van Eden W., Van Berkel T. J. C., Kuiper J., Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006 114 18 1968 1976 2-s2.0-33750502631 10.1161/CIRCULATIONAHA.106.615609 (Pubitemid 44665392)
110. Van Puijvelde G. H. M., Van Es T., Van Wanrooij E. J. A., Habets K. L. L., De Vos P., Van Der Zee R., Van Eden W., Van Berkel T. J. C., Kuiper J., Induction of oral tolerance to HSP60 or an HSP60-peptide activates t cell regulation and reduces atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 12 2677 2683 2-s2.0-36348993684 10.1161/ATVBAHA.107. 151274 (Pubitemid 350158922)
111. Mallat Z., Tedgui A., Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Expert Opinion on Biological Therapy 2004 4 9 1387 1393 2-s2.0-4544357154 10.1517/14712598.4.9.1387 (Pubitemid 39222972)
112. Fredrikson G. N., Hedblad B., Berglund G., Alm R., Ares M., Cercek B., Chyu K. Y., Shah P. K., Nilsson J., Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 872 878 2-s2.0-0038222531 10.1161/01.ATV.0000067935.02679.B0 (Pubitemid 36566180)
113. Fredrikson G. N., Lindholm M. W., Ljungcrantz I., Söderberg I., Shah P. K., Nilsson J., Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice. Autoimmunity 2007 40 2 122 130 2-s2.0-34250319739 10.1080/08916930601165107
114. Hörkkö S., Binder C. J., Shaw P. X., Chang M.-K., Silverman G., Palinski W., Witztum J. L., Immunological responses to oxidized LDL. Free Radical Biology and Medicine 2000 28 12 1771 1779 2-s2.0-0343602817 10.1016/S0891-5849(00)00333-6 (Pubitemid 30628664)
115. Shaw P. X., Hörkkö S., Tsimikas S., Chang M. K., Palinski W., Silverman G. J., Chen P. P., Witztum J. L., Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 8 1333 1339 2-s2.0-0035573706 (Pubitemid 34219841)
116. Virella G., Lopes-Virella M. F., Binder C. J., Witztum J. L., Humoral immunity and atherosclerosis. Nature Medicine 2003 9 3 243 245 2-s2.0-0037348321 10.1038/nm0303-243 (Pubitemid 36362765)
117. Fredrikson G. N., Söderberg I., Lindholm M., Dimayuga P., Chyu K. Y., Shah P. K., Nilsson J., Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 879 884 2-s2.0-0038639407 10.1161/01.ATV.0000067937. 93716.DB (Pubitemid 36566181)
118. Fredrikson G. N., Schiopu A., Berglund G., Alm R., Shah P. K., Nilsson J., Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007 194 2 e188 e192 2-s2.0-34848825887 10.1016/j. atherosclerosis.2006.12.014 (Pubitemid 47513114)